United States-based Lyndra Therapeutics has collaborated with United States-based Gilead Sciences Inc to develop and commercialise ultra-long-acting oral HIV therapies, it was reported yesterday.

Gilead Sciences Inc will have exclusive rights to Lyndra's therapeutics platform for ultra-long-acting formulations related to HIV. The formulations are claimed to have the potential to improve medication adherence by allowing patients to take a pill once a week, or even less frequently, rather than daily.

Amy Schulman, CEO and co-founder of Lyndra Therapeutics, said, 'Gilead has led the way in HIV prevention and treatment by focusing on reducing pill burden through the development of single-tablet oral regimens for their therapies, addressing an epidemic that affects nearly 40 million people globally. At Lyndra, our commitment to HIV is foundational and we are delighted to continue to work with strong research and development partners such as the Bill & Melinda Gates Foundation and, now, Gilead.'

Gilead joined Lyndra's oversubscribed USD60.9m Series B financing round a few months ago.